HDACi mediate UNG2 depletion, dysregulated genomic uracil and altered expression of oncoproteins and tumor suppressors in B- and T-cell lines

HDACi mediate UNG2 depletion, dysregulated genomic uracil and altered expression of oncoproteins and tumor suppressors in B- and T-cell lines

Abstract Background HDAC inhibitors (HDACi) belong to a new group of chemotherapeutics that are increasingly used in the treatment of lymphocyte-derived malignancies, but their mechanisms of action remain poorly understood. Here we aimed to identify novel protein targets of HDACi in B- and T-lymphom...

Full description

Bibliographic Details
Main Authors: Tobias S. Iveland, Lars Hagen, Animesh Sharma, Mirta M. L. Sousa, Antonio Sarno, Kristian Lied Wollen, Nina Beate Liabakk, Geir Slupphaug
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Journal of Translational Medicine
Subjects:
Histone deacetylase inhibitors
HDACi
Lymphoma
PCLAF
SILAC
Uracil-DNA glycosylase
Online Access:http://link.springer.com/article/10.1186/s12967-020-02318-8

Internet

http://link.springer.com/article/10.1186/s12967-020-02318-8

Similar Items